G. Thomas Budd, MD, medical oncologist, Taussig Cancer Center at Cleveland Clinic, discusses genomic profiling for targeted therapies. 

Genomic profiling is not commonly done because of the expense, Budd says, but there is pressure to make the technology more widely available available to patients. 

Budd adds that genomic profiling is still being studied in clinical trials. The NCI-MATCH trial, for example, patients will undergo genomic profiling to determine whether they have a genetic mutation or molecular abnormality that will respond to a targeted drug. 

G. Thomas Budd, MD

Articles

G. Thomas Budd on Genomic Profiling for Targeted Therapies